Bio-Thera Solutions, Ltd. (SHA:688177)
China · Delayed Price · Currency is CNY 22.29
+1.79 (8.73%)
At close: Mar 27, 2026
Bio-Thera Solutions Revenue
In the year 2025, Bio-Thera Solutions had annual revenue of 933.69M CNY with 25.64% growth. Bio-Thera Solutions had revenue of 250.10M in the quarter ending December 31, 2025, with 54.64% growth.
Revenue
933.69M
Revenue Growth
+25.64%
P/S Ratio
9.89
Revenue / Employee
746.35K
Employees
1,266
Market Cap
9.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 933.69M | 190.52M | 25.64% |
| Dec 31, 2024 | 743.17M | 38.37M | 5.44% |
| Dec 31, 2023 | 704.79M | 249.66M | 54.86% |
| Dec 31, 2022 | 455.13M | -381.45M | -45.60% |
| Dec 31, 2021 | 836.58M | 653.72M | 357.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 2.81B |
| Youcare Pharmaceutical Group | 2.45B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 2.06B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.94B |
| Nanjing Vazyme Biotech | 1.38B |
| Daan Gene | 765.48M |
| Zhejiang Ausun Pharmaceutical | 751.12M |
| Sino Biological,Inc. | 660.17M |